These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 29474204)

  • 1. Mean platelet volume and risk of thrombotic and bleeding complications in patients with Philadelphia chromosome negative myeloproliferative neoplasms.
    Krashin E; Cohen O; Pereg D; Lishner M; Leader A
    Blood Coagul Fibrinolysis; 2018 Apr; 29(3):288-293. PubMed ID: 29474204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms.
    Rungjirajittranon T; Owattanapanich W; Ungprasert P; Siritanaratkul N; Ruchutrakool T
    BMC Cancer; 2019 Feb; 19(1):184. PubMed ID: 30819138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased mean platelet volume and immature platelet fraction as potential predictors of thrombotic complications in BCR/ABL-negative myeloproliferative neoplasms.
    Kissova J; Bulikova A; Ovesna P; Bourkova L; Penka M
    Int J Hematol; 2014 Nov; 100(5):429-36. PubMed ID: 25227185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors and incidence of thrombosis in a Brazilian cohort of patients with Philadelphia-negative myeloproliferative neoplasms.
    Seguro FS; Teixeira LLC; da Rosa LI; da Silva WF; Nardinelli L; Bendit I; Rocha V
    J Thromb Thrombolysis; 2020 May; 49(4):667-672. PubMed ID: 31898273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms.
    Hasselbalch HC; Elvers M; Schafer AI
    Blood; 2021 Apr; 137(16):2152-2160. PubMed ID: 33649757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients.
    Wehmeier A; Daum I; Jamin H; Schneider W
    Ann Hematol; 1991 Aug; 63(2):101-6. PubMed ID: 1912029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms. An European Leukemia Net study.
    Martinelli I; De Stefano V; Carobbio A; Randi ML; Santarossa C; Rambaldi A; Finazzi MC; Cervantes F; Arellano-Rodrigo E; Rupoli S; Canafoglia L; Tieghi A; Facchini L; Betti S; Vannucchi AM; Pieri L; Cacciola R; Cacciola E; Cortelezzi A; Iurlo A; Pogliani EM; Elli EM; Spadea A; Barbui T
    Am J Hematol; 2014 Nov; 89(11):E200-5. PubMed ID: 25042466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How I Manage Thrombotic/Thromboembolic Complications in Myeloproliferative Neoplasms.
    Koschmieder S
    Hamostaseologie; 2020 Feb; 40(1):47-53. PubMed ID: 32050290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk Factors for and Management of MPN-Associated Bleeding and Thrombosis.
    Martin K
    Curr Hematol Malig Rep; 2017 Oct; 12(5):389-396. PubMed ID: 28948496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics and outcomes of young adults with Philadelphia-negative myeloproliferative neoplasms.
    Barzilai M; Kirgner I; Avivi I; Ellis M; Dally N; Rozovski U; Lavi N
    Eur J Haematol; 2019 Jun; 102(6):504-508. PubMed ID: 30941804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombotic and hemorrhagic events in 2016 World Health Organization-defined Philadelphia-negative myeloproliferative neoplasm.
    Song IC; Yeon SH; Lee MW; Ryu H; Lee HJ; Yun HJ; Kim SY; Jo DY
    Korean J Intern Med; 2021 Sep; 36(5):1190-1203. PubMed ID: 34289585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombotic and bleeding complications in classical myeloproliferative neoplasms.
    McMahon B; Stein BL
    Semin Thromb Hemost; 2013 Feb; 39(1):101-11. PubMed ID: 23264112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow-up of patients with portal vein thrombosis and myeloproliferative neoplasms.
    Hoekstra J; Bresser EL; Smalberg JH; Spaander MC; Leebeek FW; Janssen HL
    J Thromb Haemost; 2011 Nov; 9(11):2208-14. PubMed ID: 22040061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH).
    Appelmann I; Kreher S; Parmentier S; Wolf HH; Bisping G; Kirschner M; Bergmann F; Schilling K; Brümmendorf TH; Petrides PE; Tiede A; Matzdorff A; Griesshammer M; Riess H; Koschmieder S
    Ann Hematol; 2016 Apr; 95(5):707-18. PubMed ID: 26916570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombosis and hemorrhage in myeloproliferative neoplasms: The platelet perspective.
    Feng Y; Zhang Y; Shi J
    Platelets; 2022 Oct; 33(7):955-963. PubMed ID: 35081860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bleeding and thrombosis in chronic myeloproliferative disorders: relation of platelet disorders to clinical aspects of the disease.
    Wehmeier A; Scharf RE; Fricke S; Schneider W
    Haemostasis; 1989; 19(5):251-9. PubMed ID: 2777137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased mean platelet volume (MPV) is an independent predictor of inferior survival in patients with primary and secondary myelofibrosis.
    Lucijanic M; Mitrovic Z; Cicic D; Prka Z; Pejsa V; Livun A; Stoos-Veic T; Romic Z; Zivkovic M; Lucijanic I; Fabris Z; Kusec R
    Int J Hematol; 2018 Feb; 107(2):166-172. PubMed ID: 29022201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombotic, Vascular, and Bleeding Complications of the Myeloproliferative Neoplasms.
    Schafer AI
    Hematol Oncol Clin North Am; 2021 Apr; 35(2):305-324. PubMed ID: 33641871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort.
    Kander EM; Raza S; Zhou Z; Gao J; Zakarija A; McMahon BJ; Stein BL
    Int J Hematol; 2015 Nov; 102(5):587-93. PubMed ID: 26440973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does Race Play a Role in Complications and Outcomes of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms?
    Peseski AM; Saliba AN; Althouse SK; Sayar H
    Hematol Oncol Stem Cell Ther; 2022 Jun; 15(2):30-38. PubMed ID: 33607101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.